Report on the developments of the National Immunisation Programme: national immunisation coverage increased slightly for the first time in five years National immunisation coverage has increased for the first time in five years, for almost all vaccinations. For children born in 2017, vaccination coverage against mumps, measles and rubella (MMR) increased by 0.7% to 93.6%.
Spread of tick-borne encephalitis virus in the Netherlands Every year about 1.5 million ticks bite someone in the Netherlands, especially between March and October. Most people will not get sick of that.
Towards a sustainable, healthy future for everyone: EU project INHERIT offers policy solutions Today, on 10 December a policy toolkit will be presented at the final conference of the European four-year research project INHERIT.
Updated immunisation recommendation for measles: early vaccination before travel A number of European countries are currently seeing outbreaks of measles. Before the start of the summer season, RIVM has therefore updated its immunisation recommendation for measles.
Young people who use screens before sleeping have more sleep problems Young people (13-18 years) who use light-emitting screens daily in the hour before going to sleep have more sleep problems.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Health and Well-being through Effective Blue-Green Space Design and Governance During World Water Week (August 26 – 31, 2018), the Dutch National Institute for Public Health and the Environment, RIVM, is facilitating a session on Health and Well-being through effective Blue-G
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Risk of measles outbreaks increases with decreasing vaccination coverage Vaccination coverage for vaccinations in the Dutch National Vaccination Program (NIP) decreased slightly by about half a percent for the third consecutive year.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.